BR102375

Cat. No.: HY-128344
CAS No.: 2366255-59-4
Molecular Formula: C₃₁H₃₄N₆O₄
Molecular Weight: 554.64
Target: PARP; Apoptosis
Pathway: Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

**BIOLOGICAL ACTIVITY**

**Description**
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC₅₀ value of 0.28 μM and Aₘₐₓ ratio of 98%.[1]

**In Vitro**
BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation[1].
BR102375 (Compound 18) (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>RT-PCR[1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell Line: 3T3-L1 mouse preadipocyte cells</td>
</tr>
<tr>
<td>Concentration: 10 μM</td>
</tr>
<tr>
<td>Incubation Time:</td>
</tr>
<tr>
<td>Result: Increased AP2 and CD36 cells gene mRNA expression and enhanced glucose uptake when stimulated by insulin.</td>
</tr>
</tbody>
</table>

**In Vivo**
BR102375 (Compound 18) has decent efficacy on mouse diabetes model[1].
BR102375 reveals significant suppressive effect on random blood glucose increase(75 mpk, p.o., bid), shows decent effect on insulin resistance on Oral glucose tolerance test (OGTT) and discloses similar findings in body weight gain almost identical to Pioglitazone[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**


See more customer validations on www.MedChemExpress.com
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA